{"id":"W3215637673","doi":"10.1182/blood-2021-153795","title":"Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Medicine; Ponatinib; Internal medicine; Acute lymphocytic leukemia; Philadelphia chromosome; Oncology; Hematopoietic stem cell transplantation; Chemotherapy; Chemotherapy regimen; Clinical endpoint; Gastroenterology; Leukemia; Myeloid leukemia; Transplantation; Lymphoblastic Leukemia; Nilotinib; Clinical trial; Imatinib","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005319762,0.0008724541,0.002129542,0.0002589051,0.0002519032,0.001097574,0.0007221726,0.000673053,0.002261827],"category_scores_gemma":[0.003370122,0.0003105578,0.001218253,0.0005608089,0.0003511477,0.0009502943,0.0003732286,0.00164365,0.0006478964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008432323,"about_ca_system_score_gemma":0.001221811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009232404,"about_ca_topic_score_gemma":0.001730697,"domain_scores_codex":[0.9979487,0.001150157,0.0002173704,0.0001955096,0.0003076021,0.0001807001],"domain_scores_gemma":[0.9972366,0.0007019844,0.0007550629,0.0002468796,0.0004283256,0.0006311696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4721629,0.01420468,0.103454,0.002156293,0.007261144,0.0007661376,0.0004560754,0.004320962,0.05758503,0.000273168,0.01348121,0.3238783],"study_design_scores_gemma":[0.311417,0.2747038,0.3434664,0.0001841305,0.009458212,0.003182482,0.0002060136,0.002597684,0.01552263,0.0004599562,0.03870045,0.0001011532],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711252,0.01238437,0.001922033,0.001233484,0.0001578961,0.001878929,0.00706768,0.000157413,0.004073059],"genre_scores_gemma":[0.9749047,0.003165349,0.002466741,0.001119183,0.0001670225,0.001267733,0.01562407,0.00005649055,0.001228748],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005319762,"threshold_uncertainty_score":0.02813393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01112127825041482,"score_gpt":0.2829699702927426,"score_spread":0.2718486920423278,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}